How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California?

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6050-6050
Author(s):  
Manali I. Patel ◽  
Ellen T. Chang ◽  
Scarlett Lin Gomez ◽  
Clayton Schupp ◽  
Heather A. Wakelee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Foreign Born ◽  
Small Cell Lung ◽  
Specific Mortality ◽  
Hispanic Patients ◽  
Risk Of Disease ◽  
Disease Specific Mortality

6050 Background: Hispanics in the United States have a lower age-adjusted incidence and mortality rate from non-small cell lung cancer compared with non-Hispanic whites. Previous studies have demonstrated the influence of nativity on survival among Hispanic patients but no studies have evaluated the interplay of nativity, clinical factors, social factors, and neighborhood factors on survival among Hispanic patients with non-small cell lung cancer. Methods: All Hispanic patients with non-small cell lung cancer between the years of 1988-2008 were identified in the California Cancer Registry (CCR). Kaplan Meier curves depict survival by nativity status among Hispanics with non-small cell lung cancer. Cox proportional hazard models estimate the hazard of mortality by race with adjustment for individual covariates (age, gender, marital status), clinical factors (histologic grade, surgery, radiation, and chemotherapy), and social and neighborhood factors (neighborhood and ethnic enclave status). Results: A total of 4,062 Hispanic patients with non small cell lung cancer were included. Overall, there was a 7% decreased risk of disease-specific mortality for foreign-born patients as compared with US-born patients (HR 0.93, p=0.08, 95% CI 0.87-1.00) although not-statistically significant. Adjustment for individual patient factors and clinical factors conferred a statistically significant 16% decreased risk of disease-specific mortality compared with US-born patients (HR 0.84, p<0.0001, 95% CI 0.78-0.91). Adjustment for socioeconomic status and neighborhood socioeconomic and ethnic enclave status did not explain the differences in survival (HR 0.84, p <0.001, 95% CI 0.78-0.91). Conclusions: Overall, foreign-born Hispanics with non-small cell lung cancer have a decreased risk of disease-specific mortality compared with US-born Hispanics with non-small cell lung cancer but social factors do not explain this survival advantage. Further investigation is needed to understand the drivers of the survival advantage outcomes in foreign-born populations.

scholarly journals How Do Social Factors Explain Outcomes in Non–Small-Cell Lung Cancer Among Hispanics in California? Explaining the Hispanic Paradox

2013 ◽  
Vol 31 (28) ◽  
pp. 3572-3578 ◽  
Author(s):  
Manali I. Patel ◽  
Clayton W. Schupp ◽  
Scarlett L. Gomez ◽  
Ellen T. Chang ◽  
Heather A. Wakelee
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Survival Advantage ◽  
Foreign Born ◽  
Small Cell Lung ◽  
Neighborhood Factors ◽  
Specific Mortality ◽  
Risk Of Disease ◽  
Disease Specific Mortality ◽  
Disease Specific

Purpose Hispanics in the United States have lower age-adjusted mortality resulting from non–small-cell lung cancer (NSCLC) compared with non-Hispanic whites (NHWs). The purpose of this study was to evaluate individual, clinical, and neighborhood factors in survival among Hispanics with NSCLC. Patients and Methods We performed a retrospective analysis of NHWs and Hispanics with NSCLC between 1998 and 2007 in the California Cancer Registry (follow-up to December 2009). Kaplan-Meier curves depict survival by nativity for Hispanics with NSCLC. Cox proportional hazards models estimated hazard of mortality by race with adjustment for individual (age, sex, marital status), clinical (histologic grade, surgery, irradiation, chemotherapy), and neighborhood factors (neighborhood socioeconomic status, ethnic enclave). Results We included 14,280 Hispanic patients with NSCLC. Foreign-born Hispanics had 15% decreased risk of disease-specific mortality resulting from NSCLC compared with NHWs (hazard ratio [HR], 0.85; 95% CI, 0.83 to 0.88) after adjustment for individual, clinical, and neighborhood factors. After adjustment for individual factors, compared with US-born Hispanics, foreign-born Hispanics had 10% decreased risk of disease-specific mortality (HR, 0.90; 95% CI, 0.87 to 0.96). Clinical and neighborhood factors slightly moderated the survival benefit for foreign-born patients. A modestly more pronounced survival advantage was seen for foreign-born Hispanics living in low socioeconomic and high Hispanic enclave neighborhoods as compared with US-born Hispanics (HR, 0.86; 95% CI, 0.81 to 0.90). Conclusion Foreign-born Hispanics with NSCLC have a decreased risk of disease-specific mortality compared with NHWs and US-born Hispanics with NSCLC. Neighborhood factors slightly moderate this survival advantage. This survival advantage is slightly more pronounced in lower socioeconomic and higher Hispanic enclave neighborhoods.

scholarly journals Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer ( AB‐CLICaP )

2020 ◽  
Vol 11 (9) ◽  
pp. 2552-2560
Author(s):  
Alejandro Ruiz‐Patiño ◽  
Feliciano Barrón ◽  
Andrés F. Cardona ◽  
Luis Corrales ◽  
Luis Mas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Hispanic Patients

Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”

Lung Cancer ◽  
2015 ◽  
Vol 90 (2) ◽  
pp. 161-166 ◽  
Author(s):  
Oscar Arrieta ◽  
Laura-Alejandra Ramírez-Tirado ◽  
Renata Báez-Saldaña ◽  
Omar Peña-Curiel ◽  
Giovanny Soca-Chafre ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Characteristics ◽  
Small Cell ◽  
Hispanic Paradox ◽  
Small Cell Lung ◽  
Hispanic Patients

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort

Oncology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Zyanya Lucia Zatarain-Barrón ◽  
Andrés F. Cardona ◽  
Diego Díaz-García ◽  
Rogelio Trejo Rosales ◽  
Leonardo Rojas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Treatment Change ◽  
Genomic Alterations ◽  
Improve Treatment ◽  
Hispanic Patients

<b><i>Background:</i></b> Several studies have shown that the non-small-cell lung cancer (NSCLC) genomic background among Hispanics differs from other populations. The finding of low-frequency genomic alterations in cell-free DNA (cfDNA) can increase diagnostic accuracy and could improve treatment in NSCLC. <b><i>Methods:</i></b> Data from 54 Hispanic patients with advanced NSCLC with high clinical suspicion for <i>ALK</i>, <i>EGFR</i>, and <i>ROS1</i> mutations were collected (including young age, female sex, and non-smokers). cfDNA was extracted from plasma and analyzed using a commercial next-generation sequencing test (Guardant360) which detects genomic alterations in 74 genes. <b><i>Results:</i></b> The median age was 56 years (range 31–83). Most patients were female (661.1%) and never smokers (72.3%). Among the patients included, 96% (52/54) had cfDNA detectable alterations with a mean number of 3.37 cfDNA alterations per test (range 1–10). cfDNA was able to detect some genomic alterations previously undetected by tissue biopsy. Among patients with insufficient or unavailable tissue to perform testing, mutations in <i>EGFR</i> and <i>ALK</i> which led to a change in therapy were determined using cfDNA in 28.8 and 3.8% of cases, respectively. Among patients with cfDNA alterations, 46.1% (<i>n</i> = 24) were switched to a targeted therapy with a median progression-free survival of 11.1 months (95% CI 7.6–14.6) and an overall survival of 40.3 months (95% CI 27.1–53.6). Concurrent genetic mutations with <i>TP53</i> and <i>KRAS</i> negatively impacted the prognosis. <b><i>Conclusions:</i></b> In a selected population of NSCLC Hispanic patients, comprehensive cfDNA analysis allowed a treatment change in 46.1% of the cases. Guardant360 allows the identification of genomic alterations to improve treatment selection and increase prognosis.

Sign in / Sign up

Export Citation Format

Share Document